Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + fluorouracil + aldesleukin + interferon alfa
- Development stage
- Phase 2
- Lead developer
- Cancer Biotherapy Research Group
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
gemcitabine + fluorouracil + aldesleukin + interferon alfa is a combination chemobiotherapy regimen investigated by the Cancer Biotherapy Research Group for the treatment of metastatic or unresectable renal cell carcinoma. This regimen integrates cytotoxic chemotherapy with biological response modifiers to achieve a synergistic antitumor effect. Gemcitabine and fluorouracil are antimetabolites that interfere with DNA synthesis and repair, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Aldesleukin (recombinant interleukin-2) and interferon alfa are cytokines that modulate the host immune system, enhancing the proliferation and activity of cytotoxic T-cells and natural killer (NK) cells against tumor targets. By combining direct cytotoxicity with immune stimulation, the regimen aims to overcome the resistance often observed in advanced renal cell carcinoma.
- Other names
- Gemcitabine/5-FU/IL-2/IFN-alpha combinationChemobiotherapy (Gem/5-FU/IL-2/IFN-alpha)
02
Targets
DNAIFNAR (Immune system modulation via type I interferon receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)RNR (Ribonucleotide reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on gemcitabine + fluorouracil + aldesleukin + interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + fluorouracil + aldesleukin + interferon alfa.